Business Wire

Hopae and INCERT Partner to Make Hopae Connect the First EU-Registered Intermediary for a wide adoption and use of EU Digital Identity Wallet

8.9.2025 12:25:00 EEST | Business Wire | Press release

Share

Hopae Inc., creator of the Hopae Connect – Global eID and Wallet orchestration platform, and INCERT GIE, Luxembourg’s public trust infrastructure agency, today announced a strategic partnership to make Hopae Connect the first officially registered Intermediary Service in the EU under the eIDAS 2.0 regulation.

eIDAS 2.0 is the EU regulation that aims to deliver to every European a government-backed Digital Identity Wallet by the end of 2026—and makes it mandatory for banks, airlines, telecoms, and more to accept this new identification means. For citizens, this is a shift as big as the move from cash to contactless payment: proving who you are becomes instant, secure, and borderless. For the industry, this is a challenge given the complexity of integrating the 27 planned wallets released by the Member States. By making Hopae Connect the first EU-registered trusted intermediary, companies subject to the regulation will be able to get access to these eID and Wallet schemes easily and propose them to end user citizens.

With over 450 million Europeans to be equipped with an EUDI Wallet, the scale of change is unprecedented — and the impact will be felt in daily life:

  • Opening a bank account abroad → If I’m a French citizen living in Italy, I will be able to open a bank account in minutes online, even at 3 a.m, without the need of taking pictures of my ID document and even if the Bank is a German one.
  • At the airport → If I’m traveling abroad, I will be able to board and pass security checks with a single tap instead of juggling passports and documents.

The European Digital Identity (EUDI) Wallet, mandated for citizen login and identity verification, must be accepted by regulated digital platforms, such as the banking sector, the telecommunications sector, the gambling sector, or the healthcare one, operating in the EU by 2027. Non-compliance could result in penalties of up to 1% of global annual turnover.

To meet this challenge, Hopae and INCERT are working together to formally register Hopae Connect as the first compliant intermediary platform in Europe. This will give enterprises a ready-made, government-grade service to accept EUDI credentials and aggregate all EU Member States Digital Identity Wallets. Intermediary role has been defined in the eIDAS Architecture Reference Framework as a registered Relying Party providing services to Relying Parties.

Unlike traditional integrations built on generic cloud services, Hopae Connect will be powered by INCERT’s sovereign, eIDAS-compliant infrastructure—a trusted backend already used by some European governments providing Hopae with a Qualified Trusted Service Provider role enabling the evolution of the service to support electronic attestations. This unique design makes Hopae Connect one of the only platforms built from the ground up for regulatory-grade identity orchestration.

“Compliance at this level isn’t just a feature—it’s a foundation,” said Jaehoon Shim, CEO of Hopae. “By running Hopae Connect on INCERT’s trust infrastructure, we help our customers turn regulatory burden into competitive advantage.”

“A fully integrated ecosystem is the key to achieving seamless functionality and wide-scale usage of the EUDI wallet. ” added Benoit Poletti, CEO of INCERT. “Together with Hopae, we are laying it for trusted identity across Europe’s digital economy.”

The partners aim to complete conformity assessment and registration by the end of September 2025, well ahead of the 2027 enforcement deadline.

About Hopae:

Hopae is a digital identity infrastructure platform that helps organizations anticipate and comply with new regulations such as eIDAS 2.0, while staying competitive. Its suite of solutions provides a trusted, sovereign, and scalable foundation for digital identity — enabling higher conversion rates for businesses, reducing fraud, and ensuring more secure and self-sovereign identities for citizens.

About INCERT:

INCERT, established in 2012 by the State of Luxembourg, is a specialist in identity management and cryptographic solutions. The company's original mission was to support Luxembourg's public services, particularly in the issuance of electronic passports and ID cards, e-wallets, the digitalization of health processes, and the traceability of tobacco products. Today, INCERT offers a comprehensive ecosystem of solutions and services to both public and private clients worldwide. Its key missions are to promote digital trust and innovation, to act as a key player in the Luxembourg digital ecosystem, and to help governments and businesses preserve their digital sovereignty.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250908848131/en/

Contacts

Media contact INCERT
Karen Bornaghi +33629909493

Media contact — Hopae:
Maïlys Mas
Head of Marketing
mailys@hopae.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye